Tyra Biosciences, Inc , a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
infoTyra Biosciences is a small cap stock with a total market cap of 659.35M.
infoThey trade on the NASDAQ and had their IPO 1 year and 11 months ago.
infoTyra Biosciences currently employs 38 people.
infoAs of Wednesday, Aug 23 2023, Tyra Biosciences’s share price is $15.33.
News Relating to Tyra Biosciences
Zacks Investment Research
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
Wednesday Jun 07 2023 at 11:03
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Seeking Alpha
Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules
Thursday Jun 01 2023 at 05:25
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet.
PRNewsWire
Tyra Biosciences to Participate in Upcoming Investor Conferences
Thursday May 25 2023 at 08:00
CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: TD Cowen’s 4th Annual Oncology Innovation Summit: Todd Harris, CEO of TYRA, will participate in a virtual fireside chat on Tuesday, May 30th, 11:00 am – 11:25 am ET.
Zacks Investment Research
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for ‘Trend Investing’
Tuesday May 23 2023 at 09:53
Tyra Biosciences, Inc. (TYRA) made it through our “Recent Price Strength” screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks Investment Research
Here’s Why ‘Trend’ Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Monday Mar 27 2023 at 09:57
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our “Recent Price Strength” screen.
Zacks Investment Research
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
Wednesday Mar 01 2023 at 09:47
Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PRNewsWire
Tyra Biosciences to Present at Upcoming Investor Conferences
Thursday Nov 10 2022 at 16:20
CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November: H.C.
PRNewsWire
Tyra Biosciences to Participate at September 2022 Investor Conferences
Thursday Sep 08 2022 at 16:05
CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences: H.C.
PRNewsWire
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
Monday Sep 05 2022 at 08:15
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology (ESMO) 2022 Congress, being held in person September 9-13, 2022 in Paris, France.
Stockmarketcom
4 Health Care Stocks For Your November 2021 Watchlist
Thursday Nov 04 2021 at 12:30
Could these health care stocks be buys on President Biden’s latest vaccine mandate?
Tyra Biosciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Tyra Biosciences’s Altman Z-score is 34.26 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Tyra Biosciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $65.76K of common stock in Tyra Biosciences on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Tyra Biosciences’s Income Quality of 26.04 is greater than its Industry Group of 0.69 (3673.9% greater)
Tyra Biosciences’s Income Quality of 26.04 is greater than its Major Industry Group of 0.71 (3567.6% greater)
Tyra Biosciences’s Income Quality of 26.04 is greater than its Sector of 0.75 (3372.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Tyra Biosciences’s Current Ratio of 44.54 is greater than its Industry Group of 4.76 (835.7% greater)
Tyra Biosciences’s Current Ratio of 44.54 is greater than its Major Industry Group of 4.32 (931.0% greater)
Tyra Biosciences’s Current Ratio of 44.54 is greater than its Sector of 2.6 (1613.1% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-504.48 & -1.27)
Cannot compare a negative PE Ratio (-504.48 & -1.1)
Cannot compare a negative PE Ratio (-504.48 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Tyra Biosciences’s PB Ratio of 2.76 is greater than its Industry Group of 1.34 (106.0% greater)
Tyra Biosciences’s PB Ratio of 2.76 is greater than its Major Industry Group of 1.4 (97.1% greater)
Tyra Biosciences’s PB Ratio of 2.76 is greater than its Sector of 1.62 (70.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Tyra Biosciences’s ROE of -0.01 is greater than its Industry Group of -0.44 (97.7% greater)
Tyra Biosciences’s ROE of -0.01 is greater than its Major Industry Group of -0.38 (97.4% greater)
Tyra Biosciences’s ROE of -0.01 is greater than its Sector of -0.03 (66.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Tyra Biosciences’s ROCE of -0.24 is greater than its Industry Group of -0.42 (42.9% greater)
Tyra Biosciences’s ROCE of -0.24 is greater than its Major Industry Group of -0.37 (35.1% greater)
Tyra Biosciences’s ROCE of -0.24 is lower than its Sector of -0.04 (-500.0% lower)
Derived from SEC.GOV filing dataopen_in_new